Heterogeneity in malaria exposure and vaccine response: implications for the interpretation of vaccine efficacy trials
暂无分享,去创建一个
Chris J Drakeley | Azra C Ghani | A. Ghani | J. Griffin | C. Drakeley | M. White | Jamie T Griffin | Michael T White
[1] C. Dye,et al. Heterogeneities in the transmission of infectious agents: implications for the design of control programs. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[2] C. Dye,et al. Population dynamics of mosquito-borne disease: effects of flies which bite some people more frequently than others. , 1986, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[3] A. Prentice,et al. Impact of nutritional status on antibody responses to different vaccines in undernourished Gambian children , 2003, Acta paediatrica.
[4] Inácio Mandomando,et al. Long-term safety and efficacy of the RTS,S/AS02A malaria vaccine in Mozambican children. , 2009, The Journal of infectious diseases.
[5] J. Trape,et al. Vector density gradients and the epidemiology of urban malaria in Dakar, Senegal. , 1992, The American journal of tropical medicine and hygiene.
[6] M. Elizabeth Halloran,et al. A Frailty Mixture Model for Estimating Vaccine Efficacy , 1996 .
[7] C. Farrington,et al. Estimation of Waning Vaccine Efficacy , 2002 .
[8] M. Demoitié,et al. Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. , 2008, The New England journal of medicine.
[9] M E Halloran,et al. Interpretation and estimation of vaccine efficacy under heterogeneity. , 1992, American journal of epidemiology.
[10] M. Tanner,et al. Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants. , 2008, The New England journal of medicine.
[11] P. Carnevale,et al. Etude de l'agressivité d' Anopheles gambiae A en fonction de l'âge et du sexe des appâts humains , 1978 .
[12] S. Hay,et al. The global distribution of clinical episodes of Plasmodium falciparum malaria , 2005, Nature.
[13] R. Snow,et al. Effect of a fall in malaria transmission on morbidity and mortality in Kilifi, Kenya , 2008, The Lancet.
[14] J. Palensky,et al. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. , 2001, The Journal of infectious diseases.
[15] M. Kolczak,et al. Community-wide effects of permethrin-treated bed nets on child mortality and malaria morbidity in western Kenya. , 2003, The American journal of tropical medicine and hygiene.
[16] Thomas A. Smith,et al. Modeling a field trial of the RTS,S/AS02A malaria vaccine. , 2006, The American journal of tropical medicine and hygiene.
[17] Peter G. Smith,et al. MALVAC 2008: Measures of efficacy of malaria vaccines in phase 2b and phase 3 trials--scientific, regulatory and public health perspectives. , 2009, Vaccine.
[18] K. Marsh,et al. Analysis of Immunity to Febrile Malaria in Children That Distinguishes Immunity from Lack of Exposure , 2009, Infection and Immunity.
[19] W. Takken,et al. Odor-mediated behavior of Afrotropical malaria mosquitoes. , 1999, Annual Review of Entomology.
[20] Joe D. Cohen,et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. , 1997, The New England journal of medicine.
[21] Inacio Mandomando,et al. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial , 2004, The Lancet.
[22] R. Snow,et al. The trouble with eaves; house entry by vectors of malaria. , 1988, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[23] K. Marsh,et al. What you see is not what you get: implications of the brevity of antibody responses to malaria antigens and transmission heterogeneity in longitudinal studies of malaria immunity , 2009, Malaria Journal.
[24] M E Halloran,et al. Estimability and interpretation of vaccine efficacy using frailty mixing models. , 1996, American journal of epidemiology.
[25] I. Kleinschmidt,et al. Marked increase in child survival after four years of intensive malaria control. , 2009, The American journal of tropical medicine and hygiene.
[26] P G Smith,et al. Assessment of the protective efficacy of vaccines against common diseases using case-control and cohort studies. , 1984, International journal of epidemiology.
[27] T. Lang,et al. Malaria vaccine trial endpoints – bridging the gaps between trial design, public health and the next generation of vaccines , 2009, Parasite immunology.
[28] W. Takken,et al. Differential attractiveness of isolated humans to mosquitoes in Tanzania. , 1995, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[29] Nicolas Maire,et al. What Should Vaccine Developers Ask? Simulation of the Effectiveness of Malaria Vaccines , 2008, PloS one.
[30] Q. Bassat,et al. Insights into Long-Lasting Protection Induced by RTS,S/AS02A Malaria Vaccine: Further Results from a Phase IIb Trial in Mozambican Children , 2009, PloS one.
[31] D. Conway,et al. Changes in malaria indices between 1999 and 2007 in The Gambia: a retrospective analysis , 2008, The Lancet.
[32] J. Dushoff,et al. The entomological inoculation rate and Plasmodium falciparum infection in African children , 2005, Nature.
[33] A. Prentice,et al. Effect of month of vaccine administration on antibody responses in The Gambia and Pakistan , 2006, Tropical medicine & international health : TM & IH.
[34] D. Wypij,et al. Estimation of vaccine efficacy in a repeated measures study under heterogeneity of exposure or susceptibility to infection , 2008, Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences.